New non-oral drug delivery systems for Parkinson's disease treatment

Shadab Md, Shadabul Haque, Jasjeet Kaur Sahni, Sanjula Baboota, Javed Ali

Research output: Contribution to journalReview ArticleResearchpeer-review

23 Citations (Scopus)


Introduction: Parkinson's disease (PD) remains the only neurodegenerative disorder for which there are highly effective symptomatic therapies, but still unmet needs regarding its long-term management. Levodopa (LD) remains the most effective treatment; however, chronic use is associated with potentially disabling motor complications. Areas covered: This review highlights a variety of new non-oral drug delivery strategies for non-invasive and invasive routes of drug administration for the treatment of PD. It also includes current and future trends of liposomes, solid lipid nanoparticles and biocompatible microparticles as new non-oral drug delivery systems. Expert opinion: The long-term complications and limitations of LD treatment might be improved by changing therapy from the present pulsatile stimulation to a more constant stimulation of central dopamine receptors. Stimulation of these receptors may be possible with a new non-oral drug delivery system, with the aim of achieving long-lasting and less fluctuating drug levels, minimization of peak levels and thereby reduction of side effects.

Original languageEnglish
Pages (from-to)359-374
Number of pages16
JournalExpert Opinion on Drug Delivery
Issue number3
Publication statusPublished - 1 Mar 2011
Externally publishedYes


  • inhalational delivery
  • levodopa
  • non-oral
  • Parkinson's disease
  • transdermal delivery

Cite this